brensocatib

Brensocatib is an oral, once-daily, small-molecule, reversible inhibitor of dipeptidyl peptidase 1, also known as cathepsin C, that reduces activation of neutrophil serine proteases and is intended to dampen neutrophil-driven inflammation. The asset originated at AstraZeneca and was licensed globally to Insmed, which developed it for non-cystic fibrosis bronchiectasis and additional neutrophil-mediated diseases. It became the first approved DPP1 inhibitor and the first FDA-approved therapy specifically for non-cystic fibrosis bronchiectasis, marketed as Brinsupri; Insmed has also studied or is studying it in conditions including hidradenitis suppurativa and chronic rhinosinusitis without nasal polyps.

Brand names

Brinsupri

Other names

N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide